LAGUNA HILLS, CALIFORNIA, April 29, 2026
PreludeDx has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its innovative AidaBREAST® assay, a next-generation multi-omic diagnostic test designed for early-stage invasive breast cancer. This designation marks a significant regulatory milestone, enabling accelerated development and review pathways, and highlights the assay’s potential to transform personalized treatment decisions in oncology. AidaBREAST is designed to provide individualized risk assessment and predict the benefit of radiation therapy, addressing a critical gap in early-stage breast cancer management.
Advanced Multi-Omic Assay Enables Personalized Cancer Care
The AidaBREAST test leverages cutting-edge multi-omic technology, integrating multiplex protein expression with targeted RNA sequencing to generate a comprehensive analysis of tumor biology. By utilizing artificial intelligence-driven algorithms, the assay delivers a patient-specific prediction of 10-year locoregional recurrence risk and evaluates the potential benefit of adjuvant radiation therapy following breast-conserving surgery.
This level of precision enables clinicians to move beyond traditional diagnostic metrics, supporting more informed, data-driven treatment strategies. Importantly, AidaBREAST helps reduce both overtreatment and undertreatment, ensuring patients receive therapies that are tailored to their individual risk profiles, thereby improving outcomes and optimizing healthcare resources.
FDA Breakthrough Designation Accelerates Innovation
Advertisement
The FDA’s Breakthrough Device designation is reserved for technologies that offer significant advantages over existing diagnostic or treatment options, particularly in areas with unmet clinical needs. This designation provides priority review and enhanced regulatory support, potentially shortening the time required to bring innovative solutions to market.
For PreludeDx, this marks its second Breakthrough Device recognition, following its earlier success with DCISionRT®, reinforcing the company’s leadership in precision oncology diagnostics. The designation underscores the growing importance of advanced diagnostics in guiding personalized cancer care, especially in early-stage disease where treatment decisions can have long-term implications for patient quality of life.
Transforming Breast Cancer Treatment Decisions with AI
AidaBREAST represents a paradigm shift in breast cancer management, combining artificial intelligence, spatial biology, and genomic profiling to deliver actionable insights for clinicians and patients. Designed specifically for women with stage I and IIa invasive breast cancer, the test provides critical guidance on radiation therapy decisions, helping clinicians determine which patients are most likely to benefit from additional treatment. This approach supports a broader shift toward precision medicine, where therapies are tailored based on molecular and biological characteristics rather than one-size-fits-all protocols.
From a GxP perspective, the development of AidaBREAST aligns with high standards of clinical validation and regulatory compliance, ensuring reliability and accuracy in diagnostic performance. As PreludeDx advances the assay through the regulatory pathway, AidaBREAST is poised to become a key tool in modern oncology, improving patient outcomes, clinical efficiency, and long-term disease management.
Source: PreludeDx press release
